Comparative Clinical Study to Evaluate the Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes Inadequately Controlled by Insulin Therapy
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs Empagliflozin (Primary) ; Semaglutide (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 14 Jan 2025 New trial record